Abstract 4128
Background
E-health incorporates a range of standards, tools and activities that use electronic to deliver information, resources and services in relation to health care. Final goal is improve quality of health information, strengthening national health systems and ensuring accessible health for population with reduce costs.
Imuno-oncology uses the power of the body’s own immune system to prevent, target, control, and eliminate cancer. Most of Immune related Adverse Events are moderate, reversible if detected early and properly. Teleoncology can decrease the existing gaps between care provider and patients. Allow patients to contact with professionals, permit communication, emotional support, regular assessment and, patient empowerment during and after treatment which rise patient adherence.
Methods
Describe the use of e-health systems to promote cancer care. How e-health technology can improve cancer nurse practise and empower cancer patients receiving Immunotherapy? 3 phases: first literature review searching for e-health nurses interventions with cancer patients in last years. Second; to recruit nurses’ priorities in the 2 countries (Portugal, Spain) to assess and control adherence. Finally a multimodal pathway using e-health technology to provide a checklist for professionals will be develop.
Results
The intended results are to provide a standardized system in order to facilitate the use of e-health, for cancer patients and professionals. Display evidence-based models using a process for framing a question, locating, assessing, evaluating, and repeating it as needed. Is projected to recognize professionals needed skills to improve e-Health technologies to support cancer care, specify e-health interventions for the management of immunotherapy side effects and factors that users perceive or experience as facilitators or barriers to the uptake and implementation of eHealth technologies.
Conclusions
Technology-based interventions could be suitable for immunotherapy treatment. The study will recognize the necessary skills and e-health best system to improve nursing care, adherence and promote quality of life. Further research is required to fully assess the impact of technology as an information and support mechanism for carers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract